# Progress Note 06 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Calamity Jane (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI008-SYN-TD
- Date: 1901-05-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Ruth Ann Kessler, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Ten-week review: recovery, mood, housing and results. **S**

## History of present illness

Ms. Canary returns two weeks after her preventive visit, where she had her second naltrexone injection. She has had no alcohol for ten weeks. Cravings come mostly when she passes the bars in town in the evening, and she walks another way. Last week she moved into a rented room of her own through the housing program. For about two weeks in early April she had no phone after hers was lost, and she had no peer contact in that time; she now has a free phone through the Lifeline program. Her mood is steady. Her HPV test was negative and her tuberculosis blood test was negative. Her mammogram is booked at the mobile unit next month. **S**

| Element | Detail |
|---|---|
| Alcohol | None for ten weeks |
| Naltrexone | Injections four weeks apart; next due in two weeks |
| Housing | A rented room of her own since last week |
| Mood | PHQ-9 5; GAD-7 5 |
| Screening results | HPV negative; interferon-gamma release assay negative |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight rising |
| Gastrointestinal | Negative | No nausea or abdominal pain |
| Integumentary | Negative | Injection sites healed without lumps |
| Psychiatric | Negative | Mood steady; occasional cravings; no thoughts of suicide or self-harm |

4 systems reviewed. **S**

## Current medications

- Thiamine 100 mg oral tablet, one tablet daily **S**
- Folic acid 1 mg oral tablet, one tablet daily **S**
- Extended-release naltrexone 380 mg by deep intramuscular injection into the buttock every four weeks, given by the clinic nurse **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/76 mmHg; pulse 74 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 51.8 kg; BMI 19 kg/m². All vital signs are synthetic.

PHQ-9: 5; GAD-7: 5. All results are synthetic.

## Change since baseline

- PHQ-9: 14 at baseline, 5 at this visit **S**
- GAD-7: 11 at baseline, 5 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 118/76, pulse 74; weight 51.8 kg, BMI 19.0 |
| Skin | Buttock injection sites without induration |
| Psychiatric | Bright, joking, engaged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Severe alcohol use disorder in early remission** (F10.20). Ten weeks without alcohol on monthly naltrexone. The two weeks without peer contact in April passed without a return to drinking. Safety reviewed: no thoughts of suicide or self-harm. **S**
   - Next injection in two weeks at a nurse visit.
   - Weekly peer contact by phone; the Thursday women's meeting.
2. **Depressive symptoms during heavy drinking** (F32.A). PHQ-9 5 after ten weeks without alcohol, from 14: the symptoms have resolved without an antidepressant, consistent with alcohol-induced depressive symptoms. **S**
   - PHQ-9 at each visit; return to drinking or new low mood would prompt reassessment.
3. **Housing instability** (Z59.811). A rented room through the housing program. **S**
   - Community health worker to help with the rent assistance renewal.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Drinking since the last visit (her own account, day by day), cravings and triggers | Every visit | Completed today | No alcohol for ten weeks |
| Laboratory | PEth, explained as part of care and not as a test of honesty | At baseline and about every one to two months | Up to date | 24 ng/mL at four weeks; next at sixteen weeks |
| Medication safety | Medicine for alcohol use disorder: adherence, side effects, opioid exposure | Every visit | Completed today | Extended-release naltrexone at four weeks and eight weeks; no injection-site reaction |
| Laboratory | Liver enzymes on naltrexone | Baseline, within the first months of treatment, then periodically | Up to date | Falling at four weeks; recheck at sixteen weeks |
| Imaging | Liver fibrosis: FIB-4, transient elastography, albumin, INR, platelets | Elastography when FIB-4 is above 2.67, repeated after months without alcohol | Up to date | 9.6 kPa at four weeks; repeat at sixteen weeks |
| Examination | Weight, meals and food access | Every visit | Completed today | Weight 51.8 kg, BMI 19.0; SNAP and the food bank |
| Survey | Depression (PHQ-9) and anxiety (GAD-7) after two to four weeks without alcohol | At baseline, after two to four weeks without alcohol, then at least monthly while symptoms persist | Completed today | PHQ-9 5, item 9 scored 0; GAD-7 5 |
| Survey | Suicide-risk review, safety plan, firearm storage and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; rifle still with her friend; 988 saved in her new phone |
| Self-management | Peer recovery support and mutual-help meetings | Weekly peer contact; meetings of her choice | Deferred | No peer contact for about two weeks in early April, when she had no phone. No harm resulted: she did not drink, and she went to her Thursday meeting. Corrective action: a free Lifeline phone was arranged, and the peer specialist now confirms each week's call by text |
| Self-management | Housing, food, income and health coverage | Every visit | Completed today | A rented room of her own through the housing program; Medicaid and SNAP active |
| Self-management | Chewing tobacco | Every visit | Completed today | Still chewing; nicotine lozenges offered again |
| Medication safety | Naloxone | Reassess at every visit | Not indicated | No opioid use |

## Goal progress

- Finish withdrawal safely at home without a seizure or delirium. Outcome by 1901-03-09: Five days of gabapentin with daily nurse checks; CIWA-Ar 9 at intake, 10 at most, 2 at one week; no seizure, hallucinations or confusion. **S**
- No drinking, her goal, with a medicine for alcohol use disorder. In progress; target 1901-06-22. **S**
- Liver tests back to normal and a clear answer on liver scarring. In progress; target 1901-06-22. **S**
- Regular meals and a healthier weight. In progress; target 1901-06-22. **S**
- A room of her own and health coverage. In progress; target 1901-06-22. **S**
- PHQ-9 below 10, and reassessment once she has stopped drinking. Outcome by 1901-05-11: PHQ-9 14 to 5 after ten weeks without alcohol. **S**

## Guideline basis

- The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018), American Psychiatric Association (American Journal of Psychiatry 2018;175(1):86-90)
- The Healthcare Professional's Core Resource on Alcohol (2026), National Institute on Alcohol Abuse and Alcoholism
- Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019), American Association for the Study of Liver Diseases (Hepatology 2020;71(1):306-333)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Naltrexone injection at a nurse visit in two weeks. Sixteen-week review in six weeks with blood tests, PEth and elastography. Mammogram next month. **S**
- Next scheduled visit 1901-06-22: sixteen-week review after a two-day return to drinking: liver tests, PEth, elastography and the plan ahead. **S**
